About Longevity Diagnostics & Biomarkers
The Longevity Diagnostics & Biomarkers category is part of the Longevity & Human Enhancement market map, tracking 12 companies building in this segment. Senolytics, epigenetic reprogramming, exoskeletons, nootropics, and implantable devices pushing the boundaries of human lifespan and performance. Curated by Hartmann Capital's venture research team.
Companies in Longevity Diagnostics & Biomarkers
- GlycanAge — Series A, $8M
- TruDiagnostic — Seed, $5M
- Elysium Health — Series B, $26M
- InsideTracker — Series B, $20M
- Generation Lab — Seed, $11M
- BioAge Labs — Public, $294M
- Insilico Medicine — Series D, $400M
- Function Health — Series A, $53M
- Superpower — Series A, $30M
- Viome — Series C, $175M
- Tally Health — Seed, $10M
- Human Longevity — Series E, $370M
Frequently Asked Questions
- What companies are in the Longevity Diagnostics & Biomarkers category?
- The Longevity Diagnostics & Biomarkers category includes 12 companies: GlycanAge, TruDiagnostic, Elysium Health, InsideTracker, Generation Lab, BioAge Labs, Insilico Medicine, Function Health, Superpower, Viome, Tally Health, Human Longevity. This is part of the Longevity & Human Enhancement market map maintained by Hartmann Capital.
- How many Longevity Diagnostics & Biomarkers startups are tracked?
- Hartmann Capital tracks 12 companies in the Longevity Diagnostics & Biomarkers segment of the Longevity & Human Enhancement market map.
- What are the best funded Longevity Diagnostics & Biomarkers companies?
- Top funded companies in Longevity Diagnostics & Biomarkers include Insilico Medicine ($400M), Human Longevity ($370M), BioAge Labs ($294M), Viome ($175M), Function Health ($53M). Browse the full list in the Longevity & Human Enhancement market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.